Nuvation Bio (NUVB) Expected to Announce Quarterly Earnings on Monday

Nuvation Bio (NYSE:NUVB) is expected to be issuing its Q4 2025 results after the market closes on Monday, March 2nd. Analysts expect Nuvation Bio to post earnings of ($0.11) per share and revenue of $36.8220 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Nuvation Bio Stock Performance

Shares of Nuvation Bio stock opened at $5.92 on Friday. The firm has a market capitalization of $2.03 billion, a P/E ratio of -9.24 and a beta of 1.51. Nuvation Bio has a fifty-two week low of $1.54 and a fifty-two week high of $9.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.48 and a quick ratio of 8.39. The company’s 50 day moving average price is $6.72 and its two-hundred day moving average price is $5.48.

Analyst Ratings Changes

Several brokerages have issued reports on NUVB. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research note on Tuesday, February 10th. Citizens Jmp set a $10.00 price objective on Nuvation Bio in a report on Thursday, November 20th. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a report on Tuesday, November 4th. HC Wainwright cut their price objective on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Finally, Truist Financial set a $13.00 target price on shares of Nuvation Bio in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Insider Buying and Selling

In other news, insider Dongfang Liu sold 150,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.82, for a total value of $1,173,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at approximately $140,760. The trade was a 89.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 29.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Rangeley Capital LLC bought a new stake in shares of Nuvation Bio during the 2nd quarter valued at $25,000. Parallel Advisors LLC lifted its holdings in shares of Nuvation Bio by 51.9% during the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares in the last quarter. Cetera Investment Advisers purchased a new stake in shares of Nuvation Bio during the 2nd quarter valued at about $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio in the 2nd quarter worth approximately $32,000. Finally, Focus Partners Wealth bought a new stake in shares of Nuvation Bio in the third quarter worth $49,000. 61.67% of the stock is currently owned by institutional investors.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.